(MedPage Today) -- SILVER SPRING, Md. -- The FDA has approved flutemetamol (Vizamyl) for use with PET scans to evaluate beta-amyloid plaque burdens in the brains of living patients, making it the second such agent available in the U.S. via MedPageToday.com - medical news plus CME for physicians Read More Here..
No comments:
Post a Comment